Ketaminol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketaminol

Property Description
Active Ingredient Ketamine Hydrochloride
Primary Form Sterile Solution for Injection
Pharmacological Class General Anesthetic, NMDA Receptor Antagonist
General Purpose Anesthesia and Intense Pain Relief
Origin Synthetic Compound (Non-barbiturate)

What Type of Medicine is Ketamine?

Ketamine is fundamentally a synthetic General Anesthetic, specifically classified as a Dissociative Anesthetic. The medicine, derived from the active substance Ketamine Hydrochloride, belongs to the pharmacological class of NMDA Receptor Antagonists. The compound is a synthetic derivative of the cyclohexanone chemical structure and is clinically recognized for its unique versatility in critical care settings.

The core identity of Ketamine lies in its ability to produce a state termed "dissociative anesthesia," which significantly differentiates it from conventional anesthetic agents. This effect is achieved through the noncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor in the central nervous system, effectively interrupting signals related to conscious awareness and pain perception. This mechanism reliably provides profound analgesia (pain relief) and amnesia while consistently maintaining Systemic Stability, particularly regarding the patient’s protective airway reflexes.

Composition and Forms of the Active Ingredient

The standard pharmaceutical product is a single-agent, synthetic compound supplied predominantly as a sterile aqueous solution for injection. The active ingredient, Ketamine, is a racemic mixture containing equal proportions of two mirror-image molecular forms: S-(+)-ketamine and R-(-)-ketamine. The injectable solution is designed for rapid systemic delivery via Intravenous (IV) or Intramuscular (IM) administration. This adaptability is a key differentiating factor, making Ketamine a favored choice for providing anesthesia in settings where IV access may be difficult.

How Ketamine Works to Induce Dissociation

Ketamine works by inducing a "Brain Signaling Blockade" that causes a functional separation between the sensory and associative areas of the brain. This unique mechanism results in the patient experiencing dissociative anesthesia, leading to painlessness and lack of memory for the procedure, without necessarily inducing the deep coma associated with other anesthetic agents. The drug’s mechanism generally supports the patient’s natural breathing drive and cardiovascular function, which is a significant clinical advantage in unstable patients. This characteristic underscores its classification as an Essential Medicine.

What side effects are possible with Ketaminol?

Possible side effects and safety information

Ketaminol (Ketamine Hydrochloride) has a clearly defined safety profile in official regulatory documents, structured around effects on the central nervous, cardiovascular, and respiratory systems.

Adverse Reactions by System-Organ Class

The most commonly listed adverse effects are related to the Psychiatric/Nervous System and Cardiovascular System.

System-Organ Class Key Adverse Reaction Entities
Psychiatric/Nervous System Emergence reactions (e.g., vivid imagery, confusion, hallucinations), diplopia, nystagmus, increased cerebrospinal fluid (CSF) pressure.
Cardiovascular/Vascular Transient increase in blood pressure and heart rate (frequently elevated), hypotension, bradycardia, arrhythmia.
Respiratory Respiratory depression, apnea, and laryngospasm (especially with rapid administration).

Frequency Classification

Emergence Reactions (hallucinations, vivid dreams, delirium) have been reported to occur in approximately 12% of patients during recovery. Blood pressure and pulse rate are frequently elevated shortly after administration. Other effects, such as nausea and vomiting, are common, while severe reactions like apnea are rare.

Serious Safety Considerations

Serious adverse reactions documented in regulatory labeling include apnea (which may occur with overdosage or rapid injection), severe respiratory depression, and cardiac decompensation in susceptible patients. Additionally, haemorrhagic cystitis and hepatotoxicity (liver injury) have been reported in individuals with a history of chronic or extended use.

Safety Restrictions for Specific Populations: The drug is contraindicated in patients for whom a significant elevation of blood pressure poses a serious hazard. Caution is required in patients with pre-existing conditions such as elevated CSF pressure or severe hepatic impairment (liver disease), where a prolonged duration of action may occur. The incidence of emergence phenomena is noted to be lowest in older (geriatric) patients.

Overdose and Emergency Response

Overdosage of Ketaminol, or an overly rapid rate of intravenous administration, is officially documented to present with signs of respiratory depression, which may progress to apnea (cessation of breathing). Other documented physiological manifestations include an enhanced pressor response characterized by exaggerated elevation of blood pressure and pulse rate. Severe outcomes noted in regulatory-aligned clinical summaries can include seizure, stupor, and coma.

Urgent medical attention must be sought immediately upon the observation of severe depression of respiration or other life-threatening symptoms. Continuous monitoring of vital signs and cardiac function is mandated during management. Regulatory literature notes that instances of high-dose administration (up to ten times the usual required amount) have been followed by a prolonged, but complete, recovery.

There is no specific antidote known for Ketaminol overdosage, and primary management involves symptomatic and supportive care. If respiratory depression occurs, supportive ventilation must be employed, with mechanical support of respiration preferred over the administration of analeptics. Regulatory notes indicate a lower incidence of severe psychological manifestations (emergence phenomena) in the elderly population (over 65 years of age).

Therapeutic Uses of Ketaminol

What Ketaminol treats: main uses and benefits

Ketaminol is relevant for easing symptoms associated with acute or episodic changes where short-term symptomatic assistance is needed. It is applied across therapeutic domains, including General Anesthesia, management of Intense Acute Pain associated with trauma, and specialized protocols for Treatment-Resistant Depression (TRD) and complex Neuropathic Pain syndromes. The medication may also be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns, such as those marked by increased discomfort or tension related to bronchospasm.

In contexts involving heightened systemic burden, the medication helps address symptom clusters that may become intense or disruptive. It is commonly used in scenarios where additional management of discomfort is required, such as in emergency settings for patients with hemodynamic instability, where it may help with managing symptoms related to systemic imbalance.

“It provides support that helps ease the overall symptom burden in situations where symptoms become more noticeable.”

Quick Fact: Relief for Refractory Symptoms

The medication is applied to help provide profound pain relief and induce amnesia during procedures, contributes to easing the overall symptom load during periods of heightened symptoms, and may assist with rapid symptom management in psychiatric crises, helping patients cope more steadily with severe symptom fluctuations.

Regulatory References

  1. National Institutes of Health (NIH)

Eligibility and Restrictions for Use

The use of Ketaminol is governed by strict population-eligibility rules detailed in official regulatory documentation. The medicine is indicated for use in both adults and children for diagnostic and surgical procedures.

Eligibility Status Key Constraint
Contraindicated Known hypersensitivity to the drug or conditions where significant blood pressure elevation would be hazardous (e.g., severe uncontrolled hypertension, eclampsia, or severe coronary disease).
Not Recommended Pregnancy and Lactation, as regulatory bodies have determined that safe use in these populations has not been established.

Population Restrictions and Cautions:

  • Pediatric Patients: A warning exists regarding the potential for neurotoxicity with prolonged or repeated administration (over three hours) in the developing brain (infants up to three years of age).
  • Geriatric and Organ Function: Dose selection must be cautious in older adults. Dose reduction should be considered in patients with liver impairment due to altered drug clearance.
  • Conditional Use: Extreme caution is required in patients with pre-existing elevated cerebrospinal fluid or intraocular pressure.

What should I know about interactions with other medicines?

Ketaminol's documented interaction profile is defined by official regulatory bodies through specific pharmacokinetic (PK) and pharmacodynamic (PD) patterns, which establish important use restrictions.

The most stringent restriction concerns medicines like Theophylline or Aminophylline, as co-use is formally prohibited in regulatory documents due to an established risk of lowering the seizure threshold. Furthermore, combinations with Thyroid Hormones or agents with sympathomimetic activity (such as Vasopressin) are cautioned against due to a documented risk of marked hypertension and tachycardia, representing a significant cardiovascular effect.

Pharmacodynamic interactions occur with other Central Nervous System (CNS) Depressants, including Opioids, Benzodiazepines, and Alcohol. These substances can lead to additive CNS effects, resulting in a prolonged period of sedation and delayed recovery from the drug's primary effect.

Regarding pharmacokinetic interactions, Ketaminol is metabolized primarily by the CYP3A4 enzyme. Regulatory labeling notes that CYP3A4 Inhibitors (e.g., certain antifungals) may significantly increase Ketaminol's plasma concentration by reducing its metabolic clearance. Conversely, CYP3A4 Inducers such as the herbal product St. John's Wort are associated with the potential to decrease exposure. The relevance of these clearance-based interactions is a documented consideration for patients with hepatic impairment.

Mechanism of Action

How Ketaminol Works


Ketaminol's mechanism begins with its primary action as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the central nervous system. By physically binding within the receptor's ion channel, the drug interrupts the flow of neural signals mediated by the excitatory neurotransmitter glutamate. This interruption leads directly to a state of analgesia (altered pain perception) and altered consciousness (dissociation).

This NMDA receptor blockade initiates a rapid downstream signaling cascade involving molecular pathways like mTOR and the release of brain-derived neurotrophic factor (BDNF). This mechanism facilitates the formation and strengthening of new synaptic connections (synaptogenesis), which alters the functional organization of neural circuits. Separately, Ketaminol influences the involuntary control system by promoting the release of catecholamines (e.g., norepinephrine). This activation of the sympathetic nervous system results in the physiological consequences of an increase in heart rate and an elevation of blood pressure.

Dosage and Administration Information

How to use Ketaminol (Ketamine Hydrochloride) — Official Administration Guidelines

The use of Ketaminol (Ketamine Hydrochloride Injection) is governed by instructions for its administration as a general anesthetic. The correct procedure involves adherence to specific routes, weight-based dosing, and preparation steps.


Administration Scope

Field Official Instruction/Rule
Route of administration Intravenous (IV) Injection, Intramuscular (IM) Injection, Intravenous (IV) Infusion.
Dosing schedule (Adults) Induction (IV): Initial dose of 1 mg/kg to 4.5 mg/kg. Maintenance: Increments of one-half to the full induction dose, or a continuous IV infusion of 0.1 to 0.5 mg/minute.
Preparation requirements The 100 mg/mL concentration must be diluted before IV administration. For IV infusion, dilute to a 1 mg/mL solution using compatible fluids (e.g., Dextrose 5% in Water or 0.9% Sodium Chloride).
Age-group rules Obstetrics: IV dose ranges from 0.2 to 1.0 mg/kg. Geriatric Use: Dosing should start at the low end of the dosing range.

Resulting Procedural Structure

Official instructions mandate the following sequence to ensure proper use:

  • Premedication: An antisialagogue (e.g., atropine) may be administered prior to induction.
  • Dose Calculation: The dose is precisely determined based on the patient's body weight and the intended administration route.
  • IV Rate Control: The IV induction dose must be administered slowly over a period of 60 seconds (1 minute); faster administration is prohibited due to the risk of respiratory depression.
  • Incompatibility: Barbiturates and Ketamine are chemically incompatible and must not be injected from the same syringe.
  • Maintenance: Supplementary doses are given as-needed to sustain anesthesia.

These guidelines establish a standardized protocol for the administration of the drug in a controlled setting, defining the precise method, timing, and quantity required for use.

Recent Clinical Evidence

Research evidence / Overview of studies for Ketaminol


Evidence for Use in General Anesthesia and Sedation

Research has examined the use of Ketaminol for inducing and maintaining general anesthesia through a foundational base of non-comparative clinical studies and numerous subsequent Randomized Controlled Trials (RCTs). Research examined outcomes related to physical discomfort and measures of physiological strain and functional stability, such as heart rate, blood pressure, and the maintenance of protective airway reflexes. Studies explored the measurement of a controlled, pain-free state. The evidence base encompasses a wide range of patients, including both adult and pediatric populations across various surgical and procedural scenarios. Research describes observed patterns of physiological response that are relevant in trials assessing short-term or episodic symptom patterns.

Evidence for Acute and Perioperative Pain Management

Research concerning acute pain has been the focus of multiple systematic reviews and meta-analyses of RCTs comparing the use of Ketaminol with placebo or conventional pain relief medications. The outcomes researched included the quantification of changes in pain intensity through validated scales and the measurement of the patient’s consumption of adjunctive opioid medication. Findings describe patterns observed in the studies that were related to measured changes in pain intensity in the short-term, typically monitored over defined time intervals spanning minutes to 48 hours post-administration.

Evidence for Treatment-Resistant Depression

For patients with Treatment-Resistant Depression (TRD), research explored the use of Ketaminol using both RCTs and open-label trials. The populations studied were adults diagnosed with MDD who had not responded to multiple prior antidepressant treatments. Studies examined outcomes related to symptom intensity or variability, with the primary focus on changes in depressive symptom severity, as measured by standardized clinical rating scales. Research reports how symptoms evolved in the observed populations, indicating rapid changes measured during the study period.

What Is Still Uncertain About Ketaminol Research

A significant gap exists in understanding the patient characteristics that predict the most robust observed patterns in non-acute contexts. Furthermore, comparative evidence between different formulations or in different ethnic or socioeconomic subgroups is often uncertain. Data are still emerging to fully clarify the research gap surrounding the standardization of dose and frequency in study protocols needed to maintain any observed short-term changes. The current evidence highlights what is known — and what is still uncertain — and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Ketamine - StatPearls - NCBI Bookshelf (Review of Anesthetic and Analgesic Use)
  2. Ketamine - WHO Model List of Essential Medicines (EML)
  3. The Impact of Ketamine on Outcomes in Acute Pain Management: An Umbrella Review

Frequently Asked Questions (FAQ)

Common questions about Ketaminol (FAQ)


Q: How quickly do the effects of Ketaminol typically begin?

A: According to official product information, the time it takes for Ketaminol to take effect depends on the method of administration. For intravenous (IV) injection, the anesthetic effect usually begins within approximately 30 seconds. For intramuscular (IM) injection, the effects typically begin within 3 to 4 minutes.


Q: How long does one dose of Ketaminol usually last?

A: The duration of the main anesthetic effect is relatively short. Official documentation indicates that the effect from a single intravenous dose typically lasts about 5 to 10 minutes. The effect from an intramuscular dose usually lasts slightly longer, from 12 to 25 minutes.


Q: What happens if Ketaminol is taken with supplements like St. John's Wort?

A: Official documentation notes that certain supplements, such as St. John's Wort, may affect the concentration of Ketaminol in the body. Specifically, these products can reduce the medication's clearance, which may be a documented consideration for medical professionals.


Q: Does Ketaminol have a risk of dependence or withdrawal symptoms?

A: Ketaminol is classified as a Schedule III controlled substance by regulatory authorities. This classification indicates that the drug has an accepted medical use but possesses a potential for abuse that may lead to moderate or low physical dependence, or high psychological dependence.


Q: Is Ketaminol safe to use during pregnancy or while breastfeeding?

A: Regulatory bodies state that the safe use of Ketaminol has not been established during pregnancy or while breastfeeding. For this reason, official guidelines generally describe its use as not recommended in these populations.


Q: Can Ketaminol affect my ability to drive or operate machinery?

A: Official guidance states that the drug can impair attention, judgment, thinking, and reaction speed. Operating machinery or driving should be avoided until the day after a full, restful sleep.


Q: What types of interactions are known to happen between Ketaminol and alcohol?

A: Alcohol is a Central Nervous System (CNS) depressant. Regulatory documents caution that combining alcohol with Ketaminol can cause additive CNS effects. This may be associated with a prolonged period of sedation (sleepiness) and a delayed or prolonged recovery time.


Q: How long after stopping Ketaminol does it stay in the system?

A: Official pharmacokinetic data indicates that the terminal elimination half-life is approximately 5.2 to 6.1 hours in healthy adults. This measure describes the time it takes for half the drug to be eliminated from the body, though the main clinical effects wear off much faster.


Q: How is Ketaminol different from other common treatments for the same condition?

A: Ketaminol is uniquely classified as a Dissociative Anesthetic. Official sources state that it works by creating a functional separation between parts of the brain, leading to a state of profound painlessness and detachment from the environment, which is different from how conventional anesthetic agents function.


Q: Is Ketaminol available over-the-counter?

A: No. Because Ketaminol is classified as a Schedule III controlled substance under government regulation, it requires a prescription from a licensed healthcare provider and is not available over-the-counter.


Q: Does Ketaminol contain opioids or narcotics?

A: No. Regulatory classification documents define Ketaminol as a non-narcotic substance. While it is used for intense pain relief, its chemical structure and mechanism of action are distinct from those of opioids.


Q: Are there any specific foods or drinks that should be avoided when using Ketaminol?

A: Official information specifically mentions avoiding grapefruit or grapefruit juice. These products can reduce the medication's clearance, which may increase its concentration in the bloodstream.


Q: Is it normal to feel a little dizzy when first starting Ketaminol?

A: Official documentation lists dizziness and drowsiness as commonly reported effects related to the Nervous System. These effects often occur during the recovery period following administration.


Q: What are the official guidelines regarding the use of Ketaminol in older adults?

A: Official instructions state that dose selection must be cautious in older adults (geriatric patients). Dosing should generally begin at the low end of the dosing range due to documented changes in how the drug is cleared from the body in this population.


Q: Do children ever use Ketaminol, and under what conditions?

A: The medicine is indicated for use in both adult and pediatric populations for diagnostic and surgical procedures. However, official warnings exist regarding the potential for adverse effects with prolonged or repeated administration in the developing brain of infants up to three years of age.


Q: What is the approved duration of use for Ketaminol?

A: Ketaminol is approved for use in short-term diagnostic and surgical procedures. Its use is typically episodic, as the duration of the main anesthetic effect from a single dose is only minutes.


Q: Is Ketaminol considered a high-risk medication by health authorities?

A: It is officially categorized as a Schedule III controlled substance with accepted medical uses. Official product labeling for all prescribed medications includes documented serious safety considerations.


Q: Can Ketaminol cause changes in sleep patterns?

A: Yes, changes in sleep are noted in the official safety profile. Sleep problems, such as insomnia (difficulty sleeping), are listed as a possible adverse reaction following administration.


Q: Is Ketaminol known to interact with common over-the-counter cold medicines?

A: The drug is known to interact with certain components of cold medicines, such as those that cause Central Nervous System (CNS) depression. This combination can increase the risk of sedation, leading to prolonged drowsiness or delayed recovery.


Q: Does Ketaminol have any known long-term side effects?

A: Official documentation reports that in individuals with a history of chronic or extended use, serious adverse reactions have been documented. These include serious adverse reactions, such as haemorrhagic cystitis (bladder injury) and hepatotoxicity (liver injury).


Q: Is it possible for Ketaminol to cause an allergic reaction?

A: Yes. Official eligibility criteria state that Ketaminol is contraindicated (should not be used) in patients with known hypersensitivity to the drug itself. This refers to a severe type of allergic response.


Q: What should be done if someone accidentally takes too much Ketaminol?

A: Official management protocols for overdosage focus on supportive care. Management involves the immediate provision of supportive ventilation if breathing is compromised, alongside continuous monitoring of cardiovascular status.


Q: Are there different forms of Ketaminol (e.g., tablet, liquid, injection)?

A: The standard pharmaceutical product is supplied as a sterile aqueous solution for injection. This liquid form is designed for systemic delivery via either Intravenous (IV) or Intramuscular (IM) administration.


Q: If I am taking blood pressure medicine, is it safe to use Ketaminol?

A: Official information states that the drug is formally contraindicated in patients for whom a significant elevation in blood pressure could constitute a serious health hazard. This caution is necessary because Ketaminol can cause a transient increase in blood pressure and heart rate.


Q: Why is Ketaminol sometimes described as a 'novel' treatment?

A: It is often described as unique because of its classification as a Dissociative Anesthetic. This means it achieves painlessness and lack of memory by creating a functional separation within the brain, a state that is clinically distinct from the effects of more conventional anesthetic agents.

How should Ketaminol be stored and disposed of?

How to Store and Dispose of Ketamine

Ketamine Hydrochloride Injection must be stored under specific regulatory conditions to maintain stability and comply with controlled substance requirements.


Storage Requirements

The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Storage areas must protect the product from light, and the vials must not be frozen.

As a Schedule III controlled substance, Ketamine must be kept in its original container and stored securely, typically locked up.

Stability and Disposal

Diluted solutions prepared for intravenous use are required to be used immediately. The medication must be stored out of the sight and reach of children.

Disposal of unused or expired product should follow local regulations, and the primary method recommended for controlled substances is an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketaminol found in:

A-Z Index: